Company Overview
Moolec Science SA operates as a science-based ingredient company focused on the development of ingredients for food, pet food, animal feed, and dietary supplements through the application of molecular farming technology and precision fermentation platforms located in the Cayman Islands and internationally. The company is positioned within the broader Healthcare sector, specifically functioning in the Biotechnology industry, which implies a focus on life sciences research and the commercialization of novel biological products. Currently, the entity possesses a market capitalization of $5.04M, while specific data regarding annual revenue and employee count are not disclosed in the available financial records. The market capitalization of $5.04M indicates that the company is a micro-cap entity with a relatively small total equity value, suggesting it operates with limited scale compared to larger, established biotechnology firms. The absence of disclosed revenue and employee figures further contextualizes the company's position as an early-stage or niche player where traditional scaling metrics have not yet been fully materialized or reported to the public.
Financial Health
The available financial records indicate that revenue, net income, and EBITDA are all listed as N/A, meaning no specific figures are currently disclosed for these line items. Because revenue and net income are both unavailable, a direct gap analysis between revenue and net income to reveal cost structure details cannot be performed with the current data. Similarly, the free cash flow is listed as N/A, which prevents a definitive assessment of the company's financial flexibility or its ability to fund operations and investments from internal cash generation. The gross margin is reported at 0.0%, the operating margin is 0.0%, and the profit margin is 0.0%; these zero or near-zero margin figures often characterize early-stage biotechnology companies that have not yet achieved commercial profitability. Comparing total cash versus total debt is not possible as both cash and debt are listed as N/A, and consequently, the debt-to-equity ratio is also unavailable, preventing an analysis of whether the balance sheet is conservative or leveraged. The current ratio is listed as N/A, so it cannot be stated whether the company possesses sufficient short-term liquid assets to cover its short-term liabilities. Furthermore, the return on equity and return on assets are both N/A, indicating that management effectiveness in generating returns on shareholder equity and assets cannot be quantified at this time due to the lack of earnings and asset base data.
Valuation Assessment
The trailing twelve-month P/E ratio is listed as N/A, while the forward P/E is reported at -28.94; the negative forward P/E typically arises when a company is projecting losses, which aligns with the current lack of reported earnings. Since the trailing P/E is unavailable, a comparison between trailing and forward P/E to imply an expected earnings trajectory cannot be drawn from the existing data points. The price-to-book ratio is stated at 9.94, which suggests that the market values the company's equity at nearly ten times its book value, indicating a significant market premium over book value often seen in asset-light biotech firms with high intellectual property potential. The price-to-sales ratio and EV/EBITDA are both listed as N/A, meaning these alternative valuation metrics cannot be utilized to assess value relative to sales or enterprise earnings. The 52-week high is $157.05 and the 52-week low is $3.08; without a specific current price provided in the facts to calculate the exact percentage, the company's trading position relative to this extreme range remains undefined by the available numbers. The beta is listed as N/A, so it is impossible to quantify the stock's price volatility relative to the broader market using the provided data.
Growth & Income
The revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, preventing a statement on whether earnings are growing faster or slower than revenue. Because both revenue and earnings growth rates are unavailable, no explanation can be provided regarding the divergence or convergence of these growth metrics. The dividend yield is N/A and the payout ratio is 0.0%; given the N/A status of the dividend yield, the company does not appear to be a dividend payer, and the 0.0% payout ratio implies that any earnings, if they existed, are being retained rather than distributed to shareholders. Consequently, the company reinvests earnings into growth rather than paying dividends, a common strategy for biotechnology firms focused on research and development. The overall growth and income profile is characterized by a complete absence of reported growth rates and dividend payments, reflecting a capital-intensive business model where value is derived from future potential rather than current cash distributions or historical growth trajectories.